Results
- Showing results for:
- Reset all filters
Search results
-
Journal articleGoodwin GM, Aaronson ST, Alvarez O, et al., 2026,
Corrigendum to "The role of the psychedelic experience in psilocybin treatment for treatment-resistant depression" [Journal of Affective Disorders, Volume 372 (2025), Pages 523-532].
, J Affect Disord, Vol: 393 -
Journal articleNutt DJ, 2025,
Jan K. Melichar, BSc, MB, BS, MD, FRCPsych
, BJPsych Bulletin, Pages: 1-2, ISSN: 2056-4694 -
Journal articleBailey NW, Hill AT, Godfrey K, et al., 2025,
EEG is better when cleaning effectively targets artifacts
, CLINICAL NEUROPHYSIOLOGY, Vol: 180, ISSN: 1388-2457- Cite
- Citations: 1
-
Journal articlePurple RJ, Gupta R, Thomas CW, et al., 2025,
Correction: Short- and long-term modulation of rat prefrontal cortical activity following single doses of psilocybin.
, Mol Psychiatry, Vol: 30 -
Journal articleHojlund M, Kafali HY, Kirmizi B, et al., 2025,
Efficacy, all-cause discontinuation, and safety of serotonergic psychedelics and MDMA to treat mental disorders: A living systematic review with meta-analysis
, EUROPEAN NEUROPSYCHOPHARMACOLOGY, Vol: 101, Pages: 41-55, ISSN: 0924-977X -
Journal articleIrrmischer M, Aqil M, Luan L, et al., 2025,
DMT-induced shifts in criticality correlate with self-dissolution.
, J NeurosciPsychedelics profoundly alter subjective experience and brain dynamics. Brain oscillations express signatures of near-critical dynamics, relevant for healthy function. Alterations in the proximity to criticality have been suggested to underlie the experiential and neurological effects of psychedelics. Here, we investigate the effects of a psychedelic substance (DMT) on the criticality of brain oscillations, and in relation to subjective experience, in humans of either sex. We find that DMT shifts the dynamics of brain oscillations away from criticality in alpha and adjacent frequency bands. In this context, entropy is increased while complexity is reduced. We find that the criticality shifts observed in alpha and theta bands correlate with the intensity ratings of self-dissolution, a hallmark of psychedelic experience. Finally, using a recently developed metric, the functional excitatory-inhibitory ratio, we find that the DMT-induced criticality shift in brain oscillations is towards subcritical regimes. These findings have major implications for the understanding of psychedelic mechanisms of action in the human brain and for the neurological basis of altered states of consciousness.Significance statement Criticality is characterized by fluctuations occurring on a wide range of spatiotemporal scales and high complexity. Here, we investigate the effects of DMT, a classic psychedelic, on criticality of brain oscillations and in relation to subjective experience. We find that DMT shifts the normally dominant alpha oscillations towards a quieter subcritical state, increasing entropy while reducing complexity, and that this shift correlates with intensity of disruption of the sense of self.
-
Journal articleAlnagger NLN, Cardone P, Martial C, et al., 2025,
A Virtual Clinical Trial of Psychedelics to Treat Patients With Disorders of Consciousness
, ADVANCED SCIENCE -
Journal articleShinozuka K, Jerotic K, Mediano P, et al., 2025,
Correction: Synergistic, multi-level understanding of psychedelics: three systematic reviews and meta-analyses of their pharmacology, neuroimaging and phenomenology
, Translational Psychiatry, Vol: 15, ISSN: 2158-3188Correction to: Translational Psychiatry https://doi.org/10.1038/s41398-024-03187-1, published online 04 December 2024The meta-analysis of the 11-dimensional Altered States of Consciousness (11D-ASC) included three studies that contained duplicated data from other papers: Duerler et al. (2021), Lewis et al. (2017), and Preller et al. (2017). When these studies are removed from the analysis, the results are generally similar to the previously reported findings. Out of 33 comparisons (3 doses x 11 dimensions) between LSD and psilocybin, one becomes insignificant (insightfulness, medium dose), while one becomes more significant (disembodiment, medium dose). Note that the 5D-ASC meta-analysis did not include any duplicates, hence the results of that meta-analysis are unaffected.We also wish to acknowledge two previous meta-analyses on the phenomenology of LSD and psilocybin, respectively, by Hirschfeld and colleagues:1. Hirschfeld, T., Prugger, J., Majic, T., Schmidt, T.T. Dose-response relationships of LSD-induced subjective experiences in humans (2023). Neuropsychopharmacology, 48, 1602-1611.2. Hirschfeld, T., Schmidt, T.T. Dose-response relationships of psilocybin-induced subjective experiences in humans (2021). Journal of Psychopharmacology. 35(4), 384-397.The original article has been corrected.
-
Journal articleMartens MAG, Cunha BG, Erritzoe D, et al., 2025,
Negative affective bias in depression following treatment with psilocybin or escitalopram - a secondary analysis from a randomized trial.
, Transl Psychiatry, Vol: 15Recent clinical trial data suggests that ratings on depression scales are lowered after psilocybin therapy compared to placebo, though it is unclear what neuropsychological mechanisms underpin these effects. This study compared psilocybin, with an established antidepressant, escitalopram, to investigate whether there are shared or distinct effects on emotional information processing. Patients with long-standing moderate-to-severe depression were randomly and double-blindly assigned in a 1:1 ratio to receive either 1) two doses of 25 mg of psilocybin, 3-weeks apart, plus 6-weeks of daily placebo (psilocybin group N = 30); or 2) two doses of 1 mg of psilocybin 3-weeks apart plus 6-weeks of daily oral escitalopram (escitalopram group N = 29); all patients received the same psychological support. Behavioural measures of affective bias as well as subjective measures of depression were collected at baseline and at the primary 6-week endpoint, using an established computerised task (Facial Emotion Recognition Task) and Quick Inventory of Depressive Symptomatology, respectively. Change in affective bias was further correlated with change in depression scores measured concurrently as well as at 1-month post-trial follow-up (week-10), corrected for baseline depression severity. Negative bias in facial expression recognition decreased after both treatments to a comparable level. Concurrently, change in negative affective bias was not associated with change in depression. Longitudinally, a decrease in the misclassification of positive faces as negative was associated with a decrease in depression scores at week-10 for the escitalopram group only. Therefore, a more positive behavioural bias in emotional processing was seen following psilocybin and citalopram compared to baseline. This highlights the potential for at least some overlap in cognitive mechanisms across two distinct treatments, which is noteworthy given the short dosing regim
-
Journal articleLiardi A, Rosas FE, Carhart-Harris RL, et al., 2025,
Null models for comparing information decomposition across complex systems
, PLoS Computational Biology, Vol: 21, ISSN: 1553-734XA key feature of information theory is its universality, as it can be applied to study a broad variety of complex systems. However, many information-theoretic measures can vary significantly even across systems with similar properties, making normalisation techniques essential for allowing meaningful comparisons across datasets. Inspired by the framework of Partial Information Decomposition (PID), here we introduce Null Models for Information Theory (NuMIT), a null model-based non-linear normalisation procedure which improves upon standard entropy-based normalisation approaches and overcomes their limitations. We provide practical implementations of the technique for systems with different statistics, and showcase the method on synthetic models and on human neuroimaging data. Our results demonstrate that NuMIT provides a robust and reliable tool to characterise complex systems of interest, allowing cross-dataset comparisons and providing a meaningful significance test for PID analyses.
This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.
